When the COVID-19 vaccines began rolling out, there were initially two big ones that folks in the U.S. could choose from: Moderna and Pfizer-BioNTech. While both are completely safe in guarding against the coronavirus, the question of which one to choose was one that many people seriously considered—sometimes leading to memeified tribalism.
However, now that we’re a few years into the rollout, scientists have had time to research their effectiveness amongst certain segments of the population—and now we have a much clearer picture about which vaccine might be good for who.
Brown University researchers published a study Wednesday in the journal JAMA Network Open that found that the Moderna vaccine was linked to slightly lower incidence of adverse events than the Pfizer vaccine in adults 66 years old or older. While the authors note that both remain very safe and effective to use, they say that it might provide more concrete guidance for people’s decision making when getting vaccinated.